Acute heart failure treatment: Traditional and new drugs

Contributions to Nephrology

Volumn 165, Issue , 2010, Pages 112-128

  Gheorghiade, Mihai ^a   Palazzuoli, Alberto ^b   Ronco, Claudio ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SIENA   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT; FIBRINOLYTIC AGENT;

ACUTE DISEASE; ARTICLE; HEART FAILURE; HUMAN; METHODOLOGY; RETRACTED ARTICLE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOTONIC AGENTS; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; RESEARCH DESIGN;

EID: 77954578318     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000313750     Document Type: Article

References (27)

1. Gheorghiade M, Zannad F, Sopko G, et al: Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-3968.
2. Dickstein K, Cohen-Solal A, Filippatos G, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
3. Levy P, Compton S, Welch R, et al: Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med 2007;50:144-152.
4. Hunt SA: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46: e1-e82.
5. Jourdain P, Jondeau G, Funck F, et al: Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 2007;49:1733-1739.
6. Metra M, Ponikowski P, Dickstein K, et al, on behalf of Heart Failure Association of the European Society of Cardiology: Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007;9:684-694.
7. Gheorghiade M, Filippatos G: Reassessing treatment of acute heart failure syndromes: the ADHERE registry. Eur Heart J 2005;7(suppl): B13-B19.
8. Fonarow GC, Stough WG, Abraham WT, et al: Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768-777.
9. Gheorghiade M, Filippatos G, Pang PS, et al: Changes in clinical, neurohormonal, electrolyte, renal, and hepatic profiles during and after hospitalization for acute decompensated heart failure: analysis from the EVEREST trial (late breaking clinical trial). Paper presented at European Society of Cardiology, September 2, 2008.
10. Gheorghiade M, Pang PS: Acute heart failure syndromes. J Am Coll Cardiol 2008;53:557-573.
11. Moazemi K, Chana JS, Willard AM, Kocheril AG: Intravenous vasodilator therapy in congestive heart failure. Drugs Aging 2003;20:485-508.
12. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-1491.
13. Mitrovic V, Lüss H, Nitsche K, Forssmann K, Maronde E, Fricke K, Forssmann WG, Meyer M: Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a doubleblind, placebo-controlled, ascending-dose trial. Am Heart J 2005;150:1239.
14. Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors A, Teerlink JR, Felker GM, Metra M, Cotter G: Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009;14:321-329.
15. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
16. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP, ADHERE Scientific Advisory Committee and Investigators: Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-216.
17. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng ML, Elkayam U, for the Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-1108.
18. Anderson JL: Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J 1991;121:1956-1964.
19. Gheorghiade M, van Veldhuisen DJ, Colucci WS: Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006;113:2556-2564.
20. Cleland JG, Freemantle N, Coletta AP, Clark AL: Clinical trials update from the American Heart Association: REPAIRAMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-110.
21. Teerlink JR: A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 2009;14:289-298.
22. Cotter G, Dittrich HC, Weatherly BD, et al: The PROTECT Pilot Study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008;14:631-640.
23. Teerlink JR: The role of endothelin in the pathogenesis of heart failure. Curr Cardiol Rep 2002;4:206-212.
24. Aronson D, Burger AJ: Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol 2003;91:245-248.
25. Cotter G, Kaluski E, Stangl K, Pacher R, Richter C, Milo-Cotter O, et al: The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 2004;6:601-609.
26. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I; VERITAS Investigators: Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019.
27. Gheorghiade M, Braunwald E: Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 2009;302:2146-2147.